Recent studies have emphasized that CPT2 is pro-carcinogenic in chronic lymphocytic leukemia (CLL), epithelial ovarian cancer (EOC), gastrointestinal cancer (GIC), TNBC, etc., and that it plays an important role in promoting proliferation, migration, invasion, chemo-resistance, and radiotherapy resistance of cancer cells [10,11,94,122,123]. Here, CPT2 is linked to B-cell chronic lymphocytic leukemia.